Melissa Carpenter, Ph.D
For the last 20 years, Melissa Carpenter has worked on the development of cell therapies using human adult and embryonic stem cells, in academia and industry, in the United States and Canada. She has been involved with human embryonic stem cell (hESC) research since the field was established. Her work involves discovery research and the translation of this research into therapeutics, including developing strategies for preclinical development and navigating the regulatory issues surrounding stem cell therapies. She has held leadership positions at 3 of the major stem cell companies: CytoTherapeutics, Inc (StemCells, Inc), Geron, Corp., and Novocell, Inc (Viacyte, Inc). Currently Melissa is President of Carpenter Group Consulting and works with early stage companies, academic groups and investors to translate discovery based research into stem cell therapies. She is credited with numerous publications and patents in the stem cell field. Melissa received her B.S. from University of Oregon and her PhD from University of California, Irvine.